{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:30:03Z","timestamp":1777721403780,"version":"3.51.4"},"reference-count":32,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Chemotherapy-induced dilated cardiomyopathy (CIDCM) has become an increasingly recognized indication for heart transplantation (HT) among cancer survivors with end-stage heart failure (HF). Advances in cardio-oncology practices, mechanical circulatory support, and refined immunosuppression strategies have improved outcomes; however, comparative data with non-ischemic dilated cardiomyopathy (NIDCM) in the modern ventricular assist device (VAD) era remain limited. Therefore, this study primarily aimed to compare post-transplant outcomes between CIDCM and NIDCM within pediatric and adult cohorts in the VAD era. Methods: Data from the United Network for Organ Sharing (UNOS) registry were used to retrospectively analyze first-time orthotopic HT recipients between January 2010 and March 2023, with follow-up through March 2024. CIDCM was defined using the UNOS diagnosis codes \u201cdilated myopathy-adriamycin\u201d or \u201cdilated myopathy-cancer\u201d, whereas NIDCM included idiopathic, familial, myocarditis-related, and other specific DCM subtypes. Primary outcomes were post-HT survival, treated allograft rejection, and new or recurrent malignancy. Results: Among 28,813 recipients, 527 had CIDCM (52 pediatric, 475 adults). Pediatric survival was comparable between groups (1-, 5-, and 10-year survival: 0.92, 0.86, 0.76 vs. 0.95, 0.82, 0.68; p = 0.951). Adults with CIDCM showed superior survival (0.92, 0.82, and 0.68 vs. 0.91, 0.79, and 0.59; p = 0.018; hazard ratio (HR) 0.78 (0.64\u20130.96)) and lower rejection rates (0.03 vs. 0.04 events\/person-year; p = 0.0027), with similar incidence of post-HT malignancy. Older age, female sex, and minority race were associated with reduced survival. In pediatric recipients, age &gt;10 years and Ebstein Bar Virus (EBV) seronegativity were associated with post-HT malignancy; in adults, age \u226550 years was predictive. Conclusions: HT in CIDCM achieves durable survival and safety comparable to NIDCM. These results support expanding HT eligibility and multidisciplinary evaluation for cancer survivors with advanced HF in the contemporary era.<\/jats:p>","DOI":"10.31083\/rcm48253","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:31:56Z","timestamp":1777458716000},"source":"Crossref","is-referenced-by-count":0,"title":["Heart Transplant Outcomes in Chemotherapy-Induced vs. Non-Ischemic-Dilated Cardiomyopathy: Pediatric and Adult Recipients in the Ventricular Assist Device Era"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8785","authenticated-orcid":true,"given":"Bibhuti B.","family":"Das","sequence":"first","affiliation":[{"name":"Department of Pediatric Cardiology, Methodist Children\u2019s Hospital, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Lirette","sequence":"additional","affiliation":[{"name":"Department of Data Science, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopinath","family":"Perumal","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F, et al. Cancer treatment and survivorship statistics, 2025. CA: a Cancer Journal for Clinicians. 2025; 75: 308\u2013340.","DOI":"10.3322\/caac.70011"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, Pedersen L, B\u00fcller HR, Cronin-Fenton D, et al. Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study. JACC. CardioOncology. 2025; 7: 360\u2013378.","DOI":"10.1016\/j.jaccao.2025.03.008"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Higgins AY, O\u2019Halloran TD, Chang JD. Chemotherapy-induced cardiomyopathy. Heart Failure Reviews. 2015; 20: 721\u2013730.","DOI":"10.1007\/s10741-015-9502-y"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research. 2007; 67: 8839\u20138846.","DOI":"10.1158\/0008-5472.CAN-07-1649"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure. 2025; 31: 415\u2013455.","DOI":"10.1016\/j.cardfail.2024.08.045"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. The Journal of Heart and Lung Transplantation. 2012; 31: 805\u2013810.","DOI":"10.1016\/j.healun.2012.03.018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bock MJ, Pahl E, Rusconi PG, Boyle GJ, Parent JJ, Twist CJ, et al. Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study (PHTS) group. Pediatric Transplantation. 2017; 21: e12923.","DOI":"10.1111\/petr.12923"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Ramu B, Masotti M, Tedford RJ, Cogswell RJ. Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies. JACC. CardioOncology. 2021; 3: 294\u2013301.","DOI":"10.1016\/j.jaccao.2021.02.010"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Shah N, Aggarwal S, L\u2019Ecuyer T. Outcome of heart transplantation in pediatric cancer survivors. Pediatric Transplantation. 2013; 17: 423\u2013428.","DOI":"10.1111\/petr.12072"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Batra J, DeFilippis EM, Golob S, Clerkin K, Topkara VK, Habal MV, et al. Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. Circulation. Heart Failure. 2022; 15: e008968.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008968"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Delgado JF, Alonso-Pulp\u00f3n L, Mirabet S, Almenar L, Villa FP, Gonz\u00e1lez-V\u00edlchez F, et al. Cancer Incidence in Heart Transplant Recipients With Previous Neoplasia History. American Journal of Transplantation. 2016; 16: 1569\u20131578.","DOI":"10.1111\/ajt.13637"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. British Journal of Cancer. 2004; 91: 37\u201344.","DOI":"10.1038\/sj.bjc.6601904"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lenneman AJ, Wang L, Wigger M, Frangoul H, Harrell FE, Silverstein C, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. The American Journal of Cardiology. 2013; 111: 609\u2013612.","DOI":"10.1016\/j.amjcard.2012.10.048"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Miklin DJ, DePasquale EC. Heart transplant outcomes in restrictive cardiomyopathy: UNOS registry analysis of the last three decades. JHLT Open. 2023; 3: 100031.","DOI":"10.1016\/j.jhlto.2023.100031"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Acuna SA, Sutradhar R, Kim SJ, Baxter NN. Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study. Transplantation. 2018; 102: 1156\u20131164.","DOI":"10.1097\/TP.0000000000002178"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. The Journal of Heart and Lung Transplantation. 2023; 42: e1\u2013e222.","DOI":"10.1016\/j.healun.2022.12.004"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S, et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. The Journal of Heart and Lung Transplantation. 2024; 43: 1529\u20131628.e54.","DOI":"10.1016\/j.healun.2024.05.010"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Oliveira GH, Qattan MY, Al-Kindi S, Park SJ. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circulation. Heart Failure. 2014; 7: 1050\u20131058.","DOI":"10.1161\/CIRCHEARTFAILURE.114.001292"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Mukku RB, Fonarow GC, Watson KE, Ajijola OA, Depasquale EC, Nsair A, et al. Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy. Journal of Cardiac Failure. 2016; 22: 439\u2013448.","DOI":"10.1016\/j.cardfail.2016.04.009"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Ryan TD, Bates JE, Kinahan KE, Leger KJ, Mulrooney DA, Narayan HK, et al. Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation. 2025; 151: e926\u2013e943.","DOI":"10.1161\/CIR.0000000000001308"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022; 43: 4229\u20134361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Oliveira GH, Dupont M, Naftel D, Myers SL, Yuan Y, Tang WHW, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). Journal of the American College of Cardiology. 2014; 63: 240\u2013248.","DOI":"10.1016\/j.jacc.2013.09.040"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Guha A, Caraballo C, Jain P, Miller PE, Owusu-Guha J, Clark KAA, et al. Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure. 2021; 8: 2866\u20132875.","DOI":"10.1002\/ehf2.13362"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yamada M, L\u2019Huillier AG, Green M. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines. Journal of the Pediatric Infectious Diseases Society. 2024; 13: S31\u2013S38.","DOI":"10.1093\/jpids\/piad097"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Das B, Morrow R, Huang R, Fixler D. Persistent Epstein-Barr viral load in Epstein-Barr viral na\u00efve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. World Journal of Transplantation. 2016; 6: 729\u2013735.","DOI":"10.5500\/wjt.v6.i4.729"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Youn JC, Kim D, Kim KA, Kim JJ, Kim IC, Lee HS, et al. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy. American Journal of Transplantation. 2022; 22: 2942\u20132950.","DOI":"10.1111\/ajt.17186"},{"key":"ref27","unstructured":"Ladowski SD, Abel M, Beatty L, Scatena M, Ladowski JS. Long-term follow-up of hearttransplant recipients with pre-transplant malignancies. Texas Heart Institute Journal. 2006; 33: 27\u201330."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Vo JB, Ramin C, Veiga LHS, Brandt C, Curtis RE, Bodelon C, et al. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. Journal of the National Cancer Institute. 2024; 116: 1384\u20131394.","DOI":"10.1093\/jnci\/djae107"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Network Open. 2023; 6: e2254669.","DOI":"10.1001\/jamanetworkopen.2022.54669"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"McCormick AD, Schumacher KR, Zamberlan M, Uzark K, Yu S, Lowery R, et al. Generalized and specific anxiety in adolescents following heart transplant. Pediatric Transplantation. 2020; 24: e13647.","DOI":"10.1111\/petr.13647"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Rossano JW, Dipchand AI, Edwards LB, Goldfarb S, Kucheryavaya AY, Levvey Rn BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. The Journal of Heart and Lung Transplantation. 2016; 35: 1185\u20131195.","DOI":"10.1016\/j.healun.2016.08.018"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Cousino MK, Schumacher KR, Rea KE, Eder S, Zamberlan M, Jordan J, et al. Psychosocial functioning in pediatric heart transplant recipients and their families. Pediatric Transplantation. 2018; 22:  https:\/\/doi.org\/","DOI":"10.1111\/petr.13110"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/4\/10.31083\/RCM48253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:32:01Z","timestamp":1777458721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/4\/10.31083\/RCM48253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02748-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm48253","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"48253"}}